[HTML][HTML] Dynamic changes of CSF sTREM2 in preclinical Alzheimer's disease: the CABLE study
LZ Ma, L Tan, YL Bi, XN Shen, W Xu, YH Ma… - Molecular …, 2020 - Springer
LZ Ma, L Tan, YL Bi, XN Shen, W Xu, YH Ma, HQ Li, Q Dong, JT Yu
Molecular neurodegeneration, 2020•SpringerBackground Loss of function of triggering receptor expressed on myeloid cell 2 (TREM2), a
key receptor selectively expressed by microglia in the brain, contributes to the development
of Alzheimer's disease (AD). Whether TREM2 levels are pathologically altered during the
preclinical phase, and whether cerebrospinal fluid (CSF) soluble TREM2 protein (sTREM2)
has a relationship with major pathological processes including Aβ and tau deposition are
still unclear. Methods According to the NIA-AA criteria, 659 cognitively normal participants …
key receptor selectively expressed by microglia in the brain, contributes to the development
of Alzheimer's disease (AD). Whether TREM2 levels are pathologically altered during the
preclinical phase, and whether cerebrospinal fluid (CSF) soluble TREM2 protein (sTREM2)
has a relationship with major pathological processes including Aβ and tau deposition are
still unclear. Methods According to the NIA-AA criteria, 659 cognitively normal participants …
Background
Loss of function of triggering receptor expressed on myeloid cell 2 (TREM2), a key receptor selectively expressed by microglia in the brain, contributes to the development of Alzheimer’s disease (AD). Whether TREM2 levels are pathologically altered during the preclinical phase, and whether cerebrospinal fluid (CSF) soluble TREM2 protein (sTREM2) has a relationship with major pathological processes including Aβ and tau deposition are still unclear.
Methods
According to the NIA-AA criteria, 659 cognitively normal participants from the Chinese Alzheimer’s Biomarker and LifestylE (CABLE) cohort were divided into four groups, stage 0 (normal Aβ1–42, T-tau and P-tau), stage 1 (low Aβ1–42, normal T-tau and P-tau), stage 2 (low Aβ1–42 and high T-tau or P-tau), and suspected non-AD pathology (SNAP) (normal Aβ1–42 and high T-tau or P-tau), to examine changes of CSF sTREM2 in the preclinical AD. Biomarker cut-off was based on the assumption that one-third of adults with normal cognition have AD pathology.
Results
The level of CSF sTREM2 in the stage 1 decreased compared with the stage 0 (P < 0.001), and then increased in the stage 2 (P = 0.008). SNAP individuals also had significantly increased CSF sTREM2 (P < 0.001). Results of multiple linear regressions also showed positive correlations of CSF sTREM2 with Aβ1–42 (β = 0.192, P < 0.001), T-tau (β = 0.215, P < 0.001) and P-tau (β = 0.123, P < 0.001).
Conclusion
CSF sTREM2 levels are dynamic in preclinical AD. Aβ pathology is associated with a decrease in CSF sTREM2 in the absence of tau deposition and neurodegeneration. However, tau pathology and neurodegeneration are associated with an increase in CSF sTREM2.
Springer